EUVIMEDOdkrijte EUVIMED
Crossref

Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti‐Thymocyte Globulin

Feng-Mei Zheng, Jun Kong, Jing-Zhi Wang, Zhi-Dong Wang, Feng-Rong Wang, Ting-Ting Han, Hai-Xia Fu, Wei Han, Yuan-Yuan Zhang, Chen-Hua Yan, Huan Chen, Yao Chen and 10 more

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70242 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Feng-Mei Zheng and 21 co-authors. Institution: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Major MEDLINE topics: Antilymphocyte Serum, Cytokine Release Syndrome, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation. 32 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Key Program of the National Natural Science Foundation of China.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Cytokine release syndrome (CRS) after graft infusion under anti‐thymocyte globulin (ATG)–based haploidentical (haplo)‐hematopoietic stem cell transplantation is unclear.

Objective

The purpose of this study was to explore the clinical implications of CRS after graft infusion under ATG‐based haplo‐SCT. Study Design We retrospectively analyzed the data of 259 patients who underwent haplo‐SCT, graded CRS, and evaluated transplant outcomes.

Results

CRS occurred in 103/259 (39.8%) of the recipients. Severe CRS (Grades 3–5) was not observed. Fever was the most common manifestation (89.3%), and all cases occurred only after peripheral blood stem cell (PBSC) infusion. According to the multivariable analysis, being older than 55 years (OR 2.486 (1.124–5.496), p = 0.024), having higher CRP levels during conditioning (OR 3.011 (95% CI, 1.766–5.134), p < 0.001), and receiving PBSC as the sole stem cell source (OR 2.478 (95% CI, 1.077–5.700), p = 0.033) could predict the development of CRS, whereas an HCT‐CI score ≥ 2 was an independent risk factor for Grade 2 CRS (OR 4.259 (95% CI, 1.515–11.969, p = 0.006)). The 3‐year OS was not significantly different between the two groups, with 79% (95% CI, 61–97) for Grade 2 CRS and 85% (95% CI, 80–90) for Grade 0–1 CRS ( p = 0.288). The GRFS rates in the two groups were 69% (95% CI, 49–90) and 67% (95% CI, 60–74), respectively ( p = 0.644).

Conclusion

Our results suggest that CRS is common in patients receiving ATG‐based haplo‐SCT and does not affect survival.

Subjects

MeSH terms (MEDLINE)

Antilymphocyte SerumCytokine Release SyndromeTransplantation, HaploidenticalHematopoietic Stem Cell TransplantationGraft RejectionGraft vs Host DiseaseHumansMaleFemaleRetrospective StudiesMiddle AgedRisk FactorsAdultFollow-Up StudiesIncidencePrognosisGraft SurvivalYoung AdultAdolescentSurvival RateTransplantation Conditioning

Author keywords

allogeneic hematopoietic stem cell transplantationanti‐thymocyte globulincytokine release syndromehaploidentical

Substances

Antilymphocyte Serum

Authors and institutions

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.

ORCID profiles: Xiao-Dong Mo, Meng Lv, Yu-Qian Sun, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yu Wang

Funding

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Key Program of the National Natural Science Foundation of China
  • Major Program of the National Natural Science Foundation of China
  • Peking University Medicine Fund for World's Leading Discipline or Discipline Cluster Development

Cite

APA

Zheng, F. M., Kong, J., Wang, J. Z., Wang, Z. D., Wang, F. R., Han, T. T., Fu, H. X., Han, W., Zhang, Y. Y., Yan, C. H., Chen, H., Chen, Y., Chen, Y. H., Mo, X. D., Lv, M., Sun, Y. Q., Cheng, Y. F., Xu, L. P., Zhang, X. H., …, & Wang, Y. (2025). Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti‐Thymocyte Globulin. Clinical Transplantation. https://doi.org/10.1111/ctr.70242

Vancouver

Zheng FM, Kong J, Wang JZ, Wang ZD, Wang FR, Han TT, et al. Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti‐Thymocyte Globulin. Clinical Transplantation. 2025. doi:10.1111/ctr.70242

BibTeX
@article{Zheng2025,
  author = {Zheng, Feng-Mei and Kong, Jun and Wang, Jing-Zhi and Wang, Zhi-Dong and Wang, Feng-Rong and Han, Ting-Ting and Fu, Hai-Xia and Han, Wei and Zhang, Yuan-Yuan and Yan, Chen-Hua and Chen, Huan and Chen, Yao and Chen, Yu-Hong and Mo, Xiao-Dong and Lv, Meng and Sun, Yu-Qian and Cheng, Yi-Fei and Xu, Lan-Ping and Zhang, Xiao-Hui and Liu, Kai-Yan and Huang, Xiao-Jun and Wang, Yu},
  title = {Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti‐Thymocyte Globulin},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70242}
}
Start for free →